Actively Recruiting
Phase IbII Study of TQB2922 Injection Combined With TAS-102 Tablets With or Without Bevacizumab for Adults Aged 18 to 75 With RASBRAF Wild-Type Advanced Colorectal Cancer After Chemotherapy Failure
Led by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Updated on 2025-08-12
72
Participants Needed
27
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of TQB2922 combined with TAS-102, with or without bevacizumab, in adults with RASBRAF wild-type advanced colorectal cancer that cannot be removed by surgery and has not responded to prior chemotherapy treatments including oxaliplatin, fluorouracil-based drugs, and irinotecan. This is a Phase IbII multicenter clinical trial focusing on patients whose cancer has progressed after standard therapies. The study aims to find appropriate dosing and measure tumor response and progression over time. The study involves several treatment groups. In Phase Ib, participants receive TQB2922 injections intravenously every 28 days, once weekly in the first cycle and every two weeks from the second cycle, along with TAS-102 tablets taken orally twice daily on days 1 to 5 and 8 to 12 of each 28-day cycle. Some groups also receive bevacizumab intravenously every two weeks at 5 mgkg. Phase II continues with dosing based on recommended phase 2 dose levels, maintaining similar schedules for all medications. Treatment cycles repeat every 28 days. Participants will undergo regular assessments including monitoring for dose-limiting toxicities, tumor response rates, disease control, and adverse events up to 48 weeks or longer. Evaluations include imaging to measure tumor size, laboratory tests, and blood sampling to study drug behavior in the body. The trial monitors progression-free survival and antibody responses to treatment. The total observation period extends up to one year or more, ensuring close safety follow-up and detailed outcome measurement throughout the study duration.
CONDITIONS
Brief Title
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
Research Team
S
Suxia Luo, Master
S
Shegan Gao, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here